Leela Barham looked at what had happened a year after the NHS 10-Year Plan, released in July 2025, included the commitment to ...

Novartis saw its sales grow 3% in the second quarter, returning to growth after a 1% fall in the first quarter caused by ...

Despite ongoing advancements in genomics, artificial intelligence, and precision medicine, clinical trial success rates have remained low, with approximately 90-95% of drug candidates failing during ...

Lundbeck has completed patient randomisation in a pivotal trial of epilepsy candidate bexicaserin, one of its major growth ...

Jonathan Reynolds will lead the new combined Department for Business, Innovation, Science and Trade (DBIST). In the midst of appointing his Cabinet, new UK Prime Minister Andy Burnham has scrapped the ...

Illumina has unveiled a database of genomic alterations, called the Billion Cell Atlas, that can be used to identify and validate drug targets and train AI models used in drug discovery. The first ...

Bristol Myers Squibb has said it is the first life sciences company to buy a new AI supercomputing infrastructure blueprint ...

In what is thought to be South Korea's largest biopharma acquisition to date, Samsung Biologics has agreed to buy PolyPeptide ...

Three more biotechs have revealed their intentions to list on Nasdaq – BlossomHill, VogenX, and Latigo – as 2026 continues on ...

Venture financing for UK biotechs reached a five-year high in the second quarter of the year, with more than £2 billion ...

The European Commission has approved Novo Nordisk's pill formulation of weight-loss therapy Wegovy, making it the first oral ...

Fresh from signing an alliance with Novartis, Chai Discovery has raised $400 million in a third-round financing to support ...